First patients enter Peptonic Medical AB’s clinical phase 2b study
Stockholm 3rd May 2016. - Peptonic Medical AB (publ) -– a company developing pharmaceuticals based on oxytocin – today announced that the first patients have been randomised in to its phase 2b clinical study. The aim of the study is to investigate the effect of Peptonic Medical’s product candidate Vagitocin® on vaginal atrophy in menopausal and post-menopausal women.The Phase 2b study is a double-blind, placebo-controlled, multicenter study and comprise two arms of 80 patients each, in total 160 patients, in the main study. The objective of the study is to investigate the effect of